BeOne Medicines has secured approval from the European Commission (EC) for Tevimbra (tislelizumab) to be used along with ...

(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved TEVIMBRA ® (tislelizumab), in combination with gemcitabine and cisplatin, ...

The findings clarify that side effects of cancer treatments may be linked to a specific protein’s critical role in cellular ...

Recent research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some ...

Landmark research on MCL-1, a critical protein that is an attractive target for cancer drug development, helps explain why some promising cancer ...

Scientists at UC Davis discovered a small genetic difference that could explain why humans are more prone to certain cancers ...

Scientists have gained an atomic-level view of plant cells, getting to know the metacaspase 9 enzyme in the process.

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The delicate balance between cell death and regeneration is crucial for human health and longevity. Most mechanisms involved ...

A collaborative study from the University of Cologne has uncovered how a key mitochondrial protein, AIFM1 (Apoptosis-Inducing ...

Here, we investigated the safety and efficacy of PROSTVAC, a therapeutic cancer vaccine that targets prostate-specific antigen (PSA), in combination with the programmed cell death protein-1 inhibitor ...

Monoclonal antibodies (mAbs) have revolutionized immuno-oncology, with anti-programmed cell death protein 1 (PD1) mAbs emerging as key therapeutic agents in cancer treatment. This study presents the ...